OpenLB
Open Library of Bioscience
Advanced Search
CNS drugs
Mar, 2025;39 (3): 263-288.

Targeting Kv7 Potassium Channels for Epilepsy.

Emilio Perucca, Maurizio Taglialatela
Author Information
  1. Emilio Perucca: Department of Medicine (Austin Health), Melbourne Brain Center, The University of Melbourne, 245 Burgundy St., Heidelberg, VIC, 3084, Australia. emilio.perucca@unimelb.edu.au. ORCID
  2. Maurizio Taglialatela: Division of Pharmacology, Department of Neuroscience, University of Naples "Federico II", Naples, Italy. ORCID
PMID: 39853501 DOI: 10.1007/s40263-024-01155-3

Abstract

Voltage-gated Kv7 potassium channels, particularly Kv7.2 and Kv.7.3 channels, play a critical role in modulating susceptibility to seizures, and mutations in genes that encode these channels cause heterogeneous epilepsy phenotypes. On the basis of this evidence, activation of Kv7.2 and Kv.7.3 channels has long been considered an attractive target in the search for novel antiseizure medications. Ezogabine (retigabine), the first Kv7.2/3 activator introduced in 2011 for the treatment of focal seizures, was withdrawn from the market in 2017 due to declining use after discovery of its association with pigmentation changes in the retina, skin, and mucosae. A novel formulation of ezogabine for pediatric use (XEN496) has been recently investigated in children with KCNQ2-related developmental and epileptic encephalopathy, but the trial was terminated prematurely for reasons unrelated to safety. Among novel Kv7.2/3 openers in clinical development, azetukalner has shown dose-dependent efficacy against drug-resistant focal seizures with a good tolerability profile and no evidence of pigmentation-related adverse effects in early clinical studies, and it is now under investigation in phase III trials for the treatment of focal seizures, generalized tonic-clonic seizures, and major depressive disorder. Another Kv7.2/3 activator, BHV-7000, has completed phase I studies in healthy subjects, with excellent tolerability at plasma drug concentrations that exceed the median effective concentrations in a preclinical model of anticonvulsant activity, but no efficacy data in patients with epilepsy are available to date. Among other Kv7.2/3 activators in clinical development as potential antiseizure medications, pynegabine and CB-003 have completed phase I safety and pharmacokinetic studies, but results have not been yet reported. Overall, interest in targeting Kv7 channels for the treatment of epilepsy and for other indications remains strong. Future breakthroughs in this area could come from exploitation of mechanistic differences in the action of Kv7 activators, and from the development of molecules that combine Kv7 activation with other mechanisms of action.

References

Physiology (Bethesda). 2011 Oct;26(5):365-76 [PMID: 22013194]
Nat Rev Drug Discov. 2024 Sep;23(9):682-708 [PMID: 39039153]
Epilepsy Res. 2013 Jan;103(1):2-30 [PMID: 23219031]
Nat Rev Drug Discov. 2009 Dec;8(12):982-1001 [PMID: 19949402]
J Clin Pharmacol. 2002 Feb;42(2):175-82 [PMID: 11831540]
Epilepsia Open. 2019 Aug 12;4(3):452-463 [PMID: 31440726]
Neurology. 2007 Apr 10;68(15):1197-204 [PMID: 17420403]
Handb Exp Pharmacol. 2021;267:185-230 [PMID: 33860384]
Mol Biol Cell. 2013 Feb;24(3):274-84 [PMID: 23242999]
Pflugers Arch. 2020 Jul;472(7):881-898 [PMID: 32506321]
Epilepsia. 2024 Apr;65(4):833-845 [PMID: 38345387]
Eur J Pharmacol. 2022 May 15;923:174935 [PMID: 35378102]
Molecules. 2023 Jun 21;28(13): [PMID: 37446549]
Clin Pharmacol Ther. 2003 Jan;73(1):61-70 [PMID: 12545144]
ChemMedChem. 2022 Aug 17;17(16):e202200262 [PMID: 35687532]
Br J Pharmacol. 2023 Oct;180 Suppl 2:S145-S222 [PMID: 38123150]
Epilepsia Open. 2022 Mar;7(1):46-58 [PMID: 34668659]
CNS Drugs. 2006;20(7):601-8; discussion 609-10 [PMID: 16800718]
Drug Metab Dispos. 1999 May;27(5):613-22 [PMID: 10220491]
Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):127-137 [PMID: 27761601]
Pharmacol Res Perspect. 2019 Feb;7(1):e00467 [PMID: 30784208]
Epilepsy Behav. 2016 Mar;56:54-8 [PMID: 26828693]
J Biol Chem. 2000 Jul 21;275(29):22395-400 [PMID: 10787416]
Epilepsy Behav Case Rep. 2017 Jan 29;7:61-63 [PMID: 28417066]
Drugs. 2011 Nov 12;71(16):2151-78 [PMID: 22035515]
Acta Pharmacol Sin. 2023 Aug;44(8):1589-1599 [PMID: 36932231]
J Biol Chem. 2016 Feb 5;291(6):2931-7 [PMID: 26627826]
J Physiol. 2010 Jun 1;588(Pt 11):1829-40 [PMID: 20375142]
J Physiol. 2019 Feb;597(3):935-950 [PMID: 30536555]
Nat Genet. 1998 Jan;18(1):53-5 [PMID: 9425900]
J Neurosci. 2003 Jun 15;23(12):5012-9 [PMID: 12832524]
Nat Rev Neurosci. 2000 Oct;1(1):21-30 [PMID: 11252765]
J Physiol. 1961 Aug;157:484-503 [PMID: 13725578]
J Cereb Blood Flow Metab. 2020 Jun;40(6):1256-1273 [PMID: 31272312]
Epilepsia. 2020 Nov;61(11):2340-2364 [PMID: 33190243]
Epilepsia. 2022 Nov;63(11):2883-2910 [PMID: 35950617]
Front Physiol. 2020 Oct 28;11:570588 [PMID: 33192566]
Ann Neurol. 2014 Mar;75(3):382-94 [PMID: 24318194]
Neurol Genet. 2016 Aug 22;2(5):e96 [PMID: 27602407]
ChemMedChem. 2019 May 6;14(9):952-964 [PMID: 30861620]
J Gen Physiol. 2018 Dec 3;150(12):1722-1734 [PMID: 30373787]
Mol Pharmacol. 2000 Sep;58(3):591-600 [PMID: 10953053]
Epilepsy Res. 1999 Jun;35(2):99-107 [PMID: 10372563]
Pain. 2024 Sep 24;: [PMID: 39324934]
J Pharmacol Exp Ther. 2023 Feb;384(2):315-325 [PMID: 36396352]
Epilepsia. 2013 Aug;54(8):1437-43 [PMID: 23692516]
Neurosci Biobehav Rev. 2017 Jun;77:87-97 [PMID: 28279812]
ACS Med Chem Lett. 2011 Mar 31;2(6):481-4 [PMID: 24900334]
Nature. 1980 Feb 14;283(5748):673-6 [PMID: 6965523]
J Neurosci. 2006 Mar 8;26(10):2599-613 [PMID: 16525039]
Biochem Biophys Res Commun. 2023 Dec 31;689:149218 [PMID: 37976835]
Annu Rev Physiol. 1997;59:483-504 [PMID: 9074774]
J Neurosci. 2015 Jun 10;35(23):8829-42 [PMID: 26063916]
Acta Neurol Scand. 2022 Dec;146(6):699-707 [PMID: 36225112]
Cold Spring Harb Perspect Med. 2016 May 02;6(5): [PMID: 26801895]
Epilepsy Res. 2012 Nov;102(1-2):117-21 [PMID: 22771137]
Epilepsy Behav. 2024 Jul;156:109798 [PMID: 38788659]
Neurol Ther. 2022 Jun;11(2):781-796 [PMID: 35380370]
Eur J Pharmacol. 2020 Nov 15;887:173440 [PMID: 32745603]
Clin Pharmacol. 2014 Oct 13;6:149-59 [PMID: 25342921]
Mol Pharmacol. 2016 Jun;89(6):667-77 [PMID: 27005699]
Proc Natl Acad Sci U S A. 1968 Aug;60(4):1304-11 [PMID: 4299944]
Epilepsia. 2015 May;56(5):685-91 [PMID: 25880994]
J Physiol. 2017 Feb 1;595(3):663-676 [PMID: 27506413]
Nat Rev Neurosci. 2005 Nov;6(11):850-62 [PMID: 16261179]
Neurol Clin Pract. 2021 Apr;11(2):e112-e120 [PMID: 33842079]
J Neurosci. 2004 Feb 4;24(5):1236-44 [PMID: 14762142]
Neuroscientist. 2018 Aug;24(4):368-380 [PMID: 29542386]
Chem Res Toxicol. 2019 Feb 18;32(2):294-303 [PMID: 30638013]
Mol Cell. 2021 Jan 7;81(1):25-37.e4 [PMID: 33238160]
J Neurophysiol. 2021 Apr 1;125(4):1440-1449 [PMID: 33729829]
Front Physiol. 2020 Jun 23;11:583 [PMID: 32655402]
Expert Opin Ther Targets. 2003 Dec;7(6):737-48 [PMID: 14640909]
Science. 1970 Nov 13;170(3959):755-8 [PMID: 5479634]
Epilepsia. 2012 Mar;53(3):412-24 [PMID: 22220513]
Front Physiol. 2020 Sep 16;11:1004 [PMID: 33041840]
J Med Chem. 2022 Aug 25;65(16):11340-11364 [PMID: 35972998]
Ann Neurol. 2019 Aug;86(2):181-192 [PMID: 31177578]
CNS Neurosci Ther. 2024 Sep;30(9):e70002 [PMID: 39252462]
Epilepsia Open. 2019 Aug 11;4(3):464-475 [PMID: 31440727]
J Physiol. 2000 Feb 1;522 Pt 3:349-55 [PMID: 10713961]
Epilepsy Res. 2018 Jul;143:50-59 [PMID: 29660559]
Nature. 1996 Nov 7;384(6604):80-3 [PMID: 8900283]
Epilepsia. 2020 Aug;61(8):1678-1690 [PMID: 32652600]
JAMA Neurol. 2023 Nov 1;80(11):1145-1154 [PMID: 37812429]
Epilepsia. 2016 Dec;57(12):2019-2030 [PMID: 27888506]
Int J Clin Pharmacol Ther. 2013 Nov;51(11):847-53 [PMID: 24040852]
Neurobiol Dis. 2011 Jul;43(1):239-47 [PMID: 21458570]
Epilepsia. 2017 Mar;58(3):436-445 [PMID: 28139826]
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10232-7 [PMID: 20534576]
Cell Mol Life Sci. 2015 Oct;72(19):3677-93 [PMID: 26070303]
Epilepsia. 2024 Oct;65(10):2923-2934 [PMID: 39140981]
J Med Chem. 2010 Jan 28;53(2):887-96 [PMID: 20020710]
PLoS One. 2016 Feb 24;11(2):e0150095 [PMID: 26910900]
Prescrire Int. 2013 Nov;22(143):269 [PMID: 24427841]
Science. 1994 Nov 11;266(5187):1068-72 [PMID: 7973666]
Neuroscience. 2021 May 21;463:143-158 [PMID: 33836243]
Drug Discov Today. 2014 Apr;19(4):413-24 [PMID: 24333708]
J Pharmacol Exp Ther. 2008 Sep;326(3):818-28 [PMID: 18577704]
Nat Genet. 2005 Jul;37(7):733-8 [PMID: 15937479]
J Med Chem. 2021 May 13;64(9):5816-5837 [PMID: 33929863]
Hippocampus. 2024 Feb;34(2):58-72 [PMID: 38049972]
Eur J Pharmacol. 1996 May 15;303(3):163-9 [PMID: 8813562]
Neuron. 2022 Jan 19;110(2):237-247.e4 [PMID: 34767770]
Physiol Rev. 2013 Oct;93(4):1543-62 [PMID: 24137016]
Exp Neurol. 1970 Mar;26(3):571-85 [PMID: 5435740]
Neurobiol Dis. 2022 Nov;174:105860 [PMID: 36113748]
Epilepsy Behav. 2020 Jan;102:106580 [PMID: 31731109]
Neuropharmacology. 2022 Feb 1;203:108884 [PMID: 34785163]
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2116887119 [PMID: 35377796]
J Neurosci. 2014 Mar 5;34(10):3719-32 [PMID: 24599470]
Expert Rev Clin Pharmacol. 2024 May-Jun;17(5-6):423-432 [PMID: 38571335]
Epilepsia. 2023 Jul;64(7):e143-e147 [PMID: 37096745]
Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2412388121 [PMID: 39602259]
Seizure. 2018 Jul;59:132-140 [PMID: 29852413]
Epilepsia. 2020 Jun;61(6):1301-1311 [PMID: 32420627]
J Neurosci. 2004 May 12;24(19):4614-24 [PMID: 15140933]
Epilepsia. 2005 Apr;46(4):470-2 [PMID: 15816939]
Am J Hum Genet. 2017 Jul 6;101(1):65-74 [PMID: 28669405]
EMBO J. 1995 Nov 15;14(22):5532-41 [PMID: 8521810]
Science. 1998 Dec 4;282(5395):1890-3 [PMID: 9836639]
Neurotherapeutics. 2023 Apr;20(3):853-869 [PMID: 36976493]
Prog Neurobiol. 2024 Sep;240:102634 [PMID: 38834133]
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:625-648 [PMID: 28992433]
Epilepsia. 2018 Oct;59(10):1811-1841 [PMID: 30368792]
Epilepsia. 2024 Oct;65(10):2831-2857 [PMID: 39008349]
Epilepsia. 2015 Apr;56(4):647-57 [PMID: 25779225]
J Neurosci. 2004 Jan 21;24(3):592-7 [PMID: 14736843]
Annu Rev Physiol. 2003;65:453-80 [PMID: 12471170]
J Neurophysiol. 2007 Jan;97(1):283-95 [PMID: 17050829]
Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1477-1487 [PMID: 36574032]
Neurology. 2011 May 3;76(18):1555-63 [PMID: 21451152]
Neurol Sci. 2023 Nov;44(11):3819-3825 [PMID: 37442907]
Dev Neurosci. 2021;43(3-4):191-200 [PMID: 33794528]
Ther Adv Drug Saf. 2015 Feb;6(1):15-9 [PMID: 25642319]
Nat Commun. 2023 Oct 19;14(1):6632 [PMID: 37857637]
J Biol Chem. 2000 Aug 4;275(31):24089-95 [PMID: 10816588]
Neurology. 2010 Nov 16;75(20):1817-24 [PMID: 20944074]
Cell. 1999 Feb 5;96(3):437-46 [PMID: 10025409]
PLoS One. 2015 Feb 18;10(2):e0117350 [PMID: 25692982]
Nat Genet. 1996 Jan;12(1):17-23 [PMID: 8528244]
J Physiol. 2005 Aug 1;566(Pt 3):689-715 [PMID: 15890705]
Pharmacol Res Perspect. 2019 Oct 09;7(6):e00523 [PMID: 31624633]
Epilepsia. 2022 Jun;63(6):1349-1397 [PMID: 35503712]
Epilepsia. 2021 Jul;62(7):1744-1758 [PMID: 34085706]
Neurology. 2009 Feb 17;72(7):664-9 [PMID: 19221301]
Am J Physiol Cell Physiol. 2024 Mar 1;326(3):C893-C904 [PMID: 38284124]
Acta Pharmacol Sin. 2016 Jan;37(1):105-10 [PMID: 26725738]
Epileptic Disord. 2021 Oct 1;23(5):695-705 [PMID: 34519644]
Neurourol Urodyn. 2017 Feb;36(2):280-285 [PMID: 26536146]
Epilepsia. 2017 Jan;58(1):e10-e15 [PMID: 27861786]
Epilepsia. 2017 Feb;58(2):181-221 [PMID: 28111749]
Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3793-3797 [PMID: 30327146]
Ann Clin Transl Neurol. 2019 Nov;6(11):2164-2174 [PMID: 31568714]
Curr Clin Pharmacol. 2014 May;9(2):148-56 [PMID: 24219007]
Arzneimittelforschung. 2000 Dec;50(12):1063-70 [PMID: 11190770]
J Pharmacol Exp Ther. 2010 Mar;332(3):811-20 [PMID: 20040580]
Seizure. 2014 Nov;23(10):878-81 [PMID: 25175006]
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4386-91 [PMID: 23440208]
Curr Clin Pharmacol. 2013 Nov;8(4):319-31 [PMID: 23342983]
Eur J Pharmacol. 1997 Oct 8;336(2-3):243-9 [PMID: 9384239]
Nat Genet. 1998 Jan;18(1):25-9 [PMID: 9425895]
Epilepsia. 2024 Oct;65(10):2858-2882 [PMID: 39171993]
Cell Res. 2021 Jan;31(1):52-61 [PMID: 32884139]
Epilepsy Res. 1996 Apr;23(3):211-23 [PMID: 8739124]
J Urol. 2004 Nov;172(5 Pt 1):2054-8 [PMID: 15540788]
Neuron. 2015 Jan 21;85(2):238-56 [PMID: 25611506]
JAMA Dermatol. 2014 Sep;150(9):984-9 [PMID: 25006968]

MeSH Term

Humans
Anticonvulsants
Epilepsy
Animals
KCNQ2 Potassium Channel
Phenylenediamines
Carbamates
KCNQ3 Potassium Channel

Chemicals

Anticonvulsants
KCNQ2 Potassium Channel
ezogabine
Phenylenediamines
Carbamates
KCNQ3 Potassium Channel
Journal Article Review

Word Cloud

Similar Articles

Cited By